ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

• Status: Recruiting
• Trial end date: 2022-12-01

Summary

This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.

• Phase: Phase 1

Details

• Lead Sponsor: QuantumLeap Healthcare Collaborative
• Collaborator: Byondis B.V.
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel; Trastuzumab